Trends in serotype distribution and disease severity in adults hospitalised with

***Streptococcus pneumoniae* infection in Bristol and Bath: a retrospective cohort study,**

2006-2022

Catherine Hyams[1,2] *, Robert Challen[3] *, David Hettle[4], Zahin Amin-Chowdhury[5], Charli Grimes[1],

Gabriella Ruffino[1], Rauri Conway[1], Robyn Heath[2], Paul North[4], Adam Malin[6], Nick A Maskell[1],

Philip Williams[4], O. Martin Williams[4], Shamez N Ladhani[5], Leon Danon [2,3], Adam Finn[1,2]

[1] Academic Respiratory Unit, Learning and Research Building, Southmead Hospital, Bristol, UK

[2] Bristol Vaccine Centre, University of Bristol, Bristol, UK

[3] Engineering Mathematics, University of Bristol, Bristol, UK

[4] Department of Microbiology, Bristol Royal Infirmary, Upper Maudlin Street, Bristol, UK

[5] Immunisation Department, UK Health Security Agency (UKHSA), London, UK

[6] Department of Respiratory Medicine, The Royal United Hospital, Bath, UK

* These authors contributed equally to the manuscript and should be considered co-first authors

Corresponding author: Dr Catherine Hyams

                             Bristol Vaccine Centre

                             39-41 St Michael's Hill

                             University of Bristol

                             Bristol, UK

                             catherine.hyams@bristol.ac.uk

Running head: Pneumococcal disease and serotype trends

Keywords: Streptococcus pneumoniae; pneumococcus; serotypes; bacterial

                 infection; respiratory infection.

Funding: CH was funded by the National Institute for Health Research [NIHR Academic Clinical Fellowship (ACF-2015-25-002). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Declarations: CH is Principal Investigator of the AvonCAP study which is an investigator-led University of Bristol study funded by Pfizer. AF is a member of the Joint Committee on Vaccination and Immunization (JCVI) and was, until December 2022, chair of the World Health Organization European Technical Advisory Group of Experts on Immunization (ETAGE) committee. In addition to receiving funding from Pfizer as Chief Investigator of this study, he leads another project investigating transmission of respiratory bacteria in families jointly funded by Pfizer and the Gates Foundation. The other authors have no relevant conflicts of interest to declare.

Word Count: 3484

Analysis date: 28 March 2023

ABSTRACT (353/350)

Background

Paediatric pneumococcal conjugate vaccination (PCV) has reduced adult PCV-serotype disease: PCV7 has greater indirect effects than PCV13. Ongoing surveillance is required to evaluate current vaccine usage and inform future vaccine deployment, particularly with respiratory infection epidemiology changing following SARS-CoV-2 emergence.

Methods and Findings

A retrospective cohort study, all adults ≥16 years admitted to three UK hospitals, 2006-2022, with pneumococcal disease. Medical records were reviewed for each clinical episode and serotype data were obtained from the UK Health Security Agency national reference laboratory.

We identified 1,501 (40.3%) cases of invasive pneumococcal disease (IPD) with known serotype, 134 (3.6%) IPD cases without serotype data, and 2,084 (56.0%) non-IPD cases, which are typically missed in national surveillance. Disease incidence increased progressively from 2006-2020, followed by a sudden decline after COVID-19 emergence and then a gradual increase to pre-pandemic levels.

Paediatric PCV7 introduction reduced adult PCV7 serotype IPD from 29.4% [24.1–35.4] of IPD in 2006-09 to 7.0% [3.7–12.7] in 2021-22. PCV13 introduction also decreased adult vaccine serotype IPD, but considerable residual adult disease remains, causing 34.3% [28.6–40.4] of IPD in 2006-09 and 21.7% [15.5–29.6] 9 in 2021-22, respectively. Serotype replacement diminished the benefits of PCV introduction: PCV20-13 and non-PCV serotypes represented 27.0% [21.9–32.9] and 9.3% [6.3–13.5] of disease in 2006-2009, and 39.5% [31.5–48.2] and 31.8% [24.4–40.2] in 2021-2022, respectively.

Serotype shifts have resulted in increasing disease caused by serotype 3 and 8, and the re-emergence of serotype 19F and 19A. These serotype shifts occurred as clinical disease severity changed, and whilst the COVID-19 pandemic disrupted disease severity trends, these have now largely reverted to previous trajectories. Patient age trended upwards and although CURB65 severity decreased there were increased ICU admission rates. Overall, inpatient mortality decreased and hospitalisation duration remained stable.

Conclusions

After 17 years of PCV use, residual pneumococcal disease due to the vaccine serotypes among hospitalised adults remains. The sharp decline in pneumococcal disease during the COVID-19 pandemic has now reversed, with increasing cases due to vaccine serotypes, especially serotype 3. Around 68.2% of cases in 2022 were potentially covered by the recently licensed 20-valent PCV.

INTRODUCTION

Streptococcus pneumoniae remains the leading bacterial cause of community-acquired pneumonia (CAP), despite widespread use of effective pneumococcal vaccines with over 100 recognised pneumococcal serotypes. In the UK, PPV23 (unconjugated 23-valent pneumococcal polysaccharide vaccine) is offered to all adults aged ≥65 years (y), and persons aged at least 2y who are at increased risk of pneumococcal disease. In September 2006, a 7-valent pneumococcal conjugate vaccine (PCV7) was implemented into the national childhood immunisation programme and replaced with a 13-valent PCV (PCV13) in April 2010. The PCVs were given at a 2+1 schedule but replaced with a 1+1 schedule in April 2020 [1]. Because PCVs prevent carriage acquisition in addition to protection against disease, both PCVs had a large and significant direct and indirect (herd) impact on pneumococcal disease caused by the respective serotypes [2–4]. By 2016/17, PCV7 serotype disease had virtually disappeared in children and decreased significantly in adults. Invasive pneumococcal disease (IPD) due to PCV13 serotypes has also declined substantially, but subsequently plateaued, with a residual incidence of 8 IPD cases per 100,000 population in England [5–7]. At the same time, pneumococcal cases due to non-PCV13 serotypes increased across all age groups, especially in older adults, resulting in no net reduction in total IPD cases in older adults in 2016/17 compared to the pre-PCV13 period: a phenomenon known as serotype replacement [5–7]. Monitoring these effects nationally is vital for planning of healthcare utilisation and developing new preventive strategies, including use of higher-valent pneumococcal vaccines [8,9].

In England, the UK Health Security Agency conducts national IPD surveillance, which includes limited data on non-invasive pneumococcal disease, clinical phenotype and disease severity [5–7]. Evidence from a large pneumococcal pneumonia cohort in Nottingham, UK suggests there

are relatively few differences between patients with PCV13 and non-PCV13 serotype respiratory infection [10]. Nevertheless, changing serotype distribution could result in changes in pneumococcal disease phenotypes, which may have implications for utilisation of available polyvalent serotype-specific pneumococcal vaccines. Furthermore, the COVID-19 pandemic has disrupted the epidemiology of multiple respiratory infections [11,12], and provided new insights into viral-bacterial-host interactions. Many countries, including the UK, implemented measures such as social distancing and school closures, intended to decrease SARS-CoV-2 transmission and alleviate pressure on healthcare services [13]. These measures reduced the transmission of other respiratory pathogens [12], but it is unclear to what extent they have disrupted pneumococcal transmission [14,15]. These measures may also have caused changes in serotype distribution of pneumococcal infection, and disease.

In this retrospective cohort study conducted at three large NHS hospitals, which represent all secondary care provision within a defined geographical area, we examined the trends in pneumococcal serotype distribution in adults following PCV7 and PCV13 implementation into the childhood immunisation programme and the effect of the COVID-19 pandemic over the first three years. We report confirmed pneumococcal disease incidence during 2006-2022, both overall and by vaccine serotypes, and assess trends in severity of pneumococcal disease in hospitalised adults.

METHODS AND MATERIALS

Study design

A retrospective cohort study was conducted including all patients aged ≥16 years that were admitted to any of three large UK NHS hospitals in southwest England - University Hospitals Bristol and Weston, North Bristol and The Royal United Hospital (Bath) NHS Trusts. The study covered the period from 01/01/2006 to 31/12/2022 and included patients with a confirmed microbiological diagnosis of pneumococcal infection. These hospitals provide all secondary care within a defined geographical area with 100,000 unplanned adult admissions annually, including the regional cardiothoracic, pleural, respiratory specialist, and general medical and respiratory services.

Eligible cases were identified retrospectively by searching the Laboratory Information Management System (LIMS) database (Clinisys WinPath Enterprise). *S. pneumoniae* was confirmed through culture or PCR from a sterile site at a central laboratory using standard microbiological techniques, the former confirmed with API®-20 Strep (BioMérieux, UK) or MALDI-TOF (matrix-assisted laser desorption/ionisation/time of flight) mass spectrometry (Bruker, UK). A positive pneumococcal urinary-antigen test [UAT] (BinaxNOW®, Alere, UK) was also considered confirmative of pneumococcal infection. Patients were included if they tested positive on any or all tests. Confirmed cases were linked with the UK Health Security Agency (UKHSA) national reference laboratory database to obtain serotype data, which were collected at the end of the study to avoid risk of bias in clinical data collection. Clinical records were reviewed at each hospital and data were recorded in a standardised manner, including laboratory and radiological investigations. Patient observations within 24 hours of clinical presentation with a pneumococcal infection were also recorded, and vaccination status was

established using electronically-linked General Practitioner (GP) records. The CURB65 severity score on admission was calculated for each clinical episode, and clinical outcomes, including length of hospitalisation and Intensive Care Unit [ICU] admission, were recorded. Inpatient mortality was determined through review of the medical records. All adults were managed at the discretion of the admitting clinical team.

Case definitions

Total pneumococcal disease included all positive cases whether identified by sterile site culture/PCR or positive UAT with clinical confirmation of sterile site infection (i.e. invasive pneumococcal disease [IPD]), or non-invasive pneumococcal disease (positive UAT only). Total cases where the serotype was identified are referred to as serotype-known disease: pneumococcal serotypes were further grouped by vaccine-serotypes: PCV7, PCV13-7, PCV15-13, PCV20-15, PCV20-13, and serotypes not contained in a PCV (non-PCV) (Supplementary Data 1). The primary infection site was derived from the managing clinician's diagnosis. Respiratory infection included both consolidative infection (i.e. pneumonia following BTS/NICE guidelines [16]) and non-pneumonic lower respiratory tract infection.

Analysis

Data are reported as medians and interquartile ranges (IQR) for continuous variables, or means and standard deviations where the distributions were confirmed to be normal using the Anderson Darling normality test. Categorical variables are presented as counts and percentages. Multinomial confidence intervals were calculated using Wilson's score interval method for binomial proportions [17] which we tested on simulated data and found to be well

calibrated for this problem. Baseline characteristics were compared using Fisher's exact tests for categorical variables, the two-sample Kolmogorov-Smirnov for non-parametric continuous variables, Wilcoxon Rank Sum test for score variables, or the two-sided Student's t-test for parametric continuous variables. There were minimal missing data, and only for categorical variables. When present they are included as a separate category prior to statistical testing.

Multinomial time series analysis was performed by fitting a single-hidden-layer neural network using the R package `nnet` [18] with a time varying natural spline term for class probabilities, and a knot point for each class every two years.

Binomial time series analysis was performed using a maximum likelihood approach using local polynomial regression using a logit link function assuming the count of positives and negatives are a quasi-binomially distributed quantity using the R package `locfit` according to the methods of Loader *et al.* [19] with a bandwidth equivalent to 2 years' worth of data and a polynomial of degree 2.

Yearly estimates for the ≥16y population of clinical commissioning groups of NHS Bath and North East Somerset and NHS Bristol, North Somerset and South Gloucestershire regions were obtained from NHS Digital. Yearly point estimates were interpolated to daily estimates using a local polynomial regression and pneumococcal disease incidence was estimated as the rate of monthly admission counts using a local polynomial regression, assuming a quasi-poisson distribution, logistic link function and the methods of Loader *et al.* [19] as above. Admission rates were expressed as disease per 1000 person years using the interpolated population estimates.

All analyses were performed using R version 4.2 [20].

Ethics Approval:

This study was approved by the Health Research Authority, UK (IRAS 265437).

Funding:

RESULTS

From 2006-2022, we identified 3,719 adults with pneumococcal disease with a median age of 66.1 years [IQR 50.2–78.9]. Of these, 1,840 (49.5%) were male, 1,621 (43.6%) had positive blood cultures, 2,379 (64.0%) were UAT positive and 15 (0.4%) were PCR-positive. Among the cases, 1,686 (45.3%) were IPD and 2,033 (54.7%) were non-invasive pneumococcal disease cases. Respiratory infection accounted for 92.3% (3436/3719) of pneumococcal disease with 84.2% being IPD and 99.2% of IPD being non-invasive pneumococcal disease (Table 1). Pneumococcal serotype was available for 1,501 (40%) cases. The demographics and clinical characteristics of patients with known-serotype pneumococcal disease were similar to those with unknown serotype infection (Supplementary Data 2).

The incidence of pneumococcal disease among hospitalised adults showed an upward trend over time. until SARS-CoV-2 emergence in 2020. Following this, there was a sudden decline followed by a gradual increase. By December 2022, the incidence had increased to a level similar to that observed before the COVID-19 pandemic (Figure 1A). PCV7-serotype disease decreased from 29.4% [24.1–35.4] in 2006-2009 to 7.0% [3.7–12.7] of serotype-known disease in 2021-2022, with PCV7-serotypes causing minimal disease from mid-2017 until their re-emergence during the COVID-19 pandemic. PCV13-7 disease represented 34.3% [28.6–40.4] of serotype-known disease in 2006-2009, decreased slightly to 29.3% [25.6–33.3] by 2010-2015, and continued to decrease to 21.7% [15.5–29.6] in 2021-2022, with serotypes 1, 3 and 19A persisting. In contrast, the proportion of PCV20-13 and non-PCV serotype disease increased during this period (Figure 1B). While blood culture testing rates remained stable over time, there were changes in UAT testing. Notably, the decreased pneumococcal disease incidence observed during the COVID-19 pandemic occurred without an equivalent decrease in

BinaxNOW and blood culture testing over the same time period (Figure 1C). Following SARS-CoV-2 emergence, the most commonly identified serotypes were 3, 8, 9N, 19F, 19A and 22F (Figure 2A,B). In 2022, 6.2% [3.2–11.8], 33.3% [25.8–41.8], and 31.8% [24.4–40.2] of disease was attributable to PCV15-13, PCV20-15 or non-PCV serotypes respectively, with a significant proportion of disease arising from serotypes in current PCVs. Among known-serotype cases, PCV7 and PCV13-7 serotypes represented 7.0% [3.7–12.7] and 21.7% [15.5–29.6] of pneumococcal disease. Overall, the proportion of disease caused by 19F, 19A and 22F remained relatively stable throughout the study, while a notable expansion of serotypes 3 and 8 disease occurred, alongside a slight increase in serotype 9N (Figure 2C).

Before the emergence of SARS-CoV-2 , the age of patients admitted with pneumococcal disease increased over time (Figure 3A) while disease severity decreased, as shown by the average CURB65 severity scores on admission (Figure 3B). ICU admission rates increased in earlier years and then plateaued, while inpatient mortality decreased and length of hospital admission remained broadly stable (Figure 3C-E). These trends were disrupted during the early stages of the SARS-CoV-2 pandemic and largely reverted to their previous trajectories in 2021-22. The proportion of patients aged 45-55y trended upwards, as compared to the pre-pandemic period, and the proportion of IPD cases requiring ICU admission also increased but these trends are based on small numbers.

Table One: Characteristics of patients hospitalised with confirmed pneumococcal infection in Bristol, 2006-2022.

Variable	Characteristic	Invasive disease Value (N=1686)	Non-invasive disease Value (N=2033)	P value
Age	Median [IQR]	65.9 [50.8—79]	66.3 [50—78.8]	0.74
Gender	Male % (N)	50.2% (847)	48.8% (993)	0.41
	Female % (N)	49.8% (839)	51.2% (1040)	
Serotype Status	Serotype identified % (N)	89.0% (1501)	0.0% (0)	<0.001
	No serotype % (N)	11.0% (185)	100.0% (2033)	
Smoker	Non-smoker % (N)	29.4% (495)	29.4% (597)	0.95
	Ex-smoker % (N)	40.3% (680)	40.8% (829)	
	Current smoker % (N)	30.3% (511)	29.9% (607)	
CCI	Median [IQR]	4 [1—6]	4 [1—6]	0.31
Test Type	Blood culture only % (N)	78.6% (1325)	0.0% (0)	<0.001
	UAT only % (N)	3.0% (51)	100.0% (2033)	
	Blood culture & UAT % (N)	17.5% (295)	0.0% (0)	
	CSF PCR % (N)	0.5% (8)	0.0% (0)	
	Blood PCR % (N)	0.4% (7)	0.0% (0)	
Infection Site	Lung % (N)	84.2% (1419)	99.2% (2017)	<0.001
	Meningitis % (N)	10.2% (172)	0.0% (0)	
	Septic arthritis % (N)	2.1% (36)	0.0% (0)	
	ENT % (N)	0.9% (15)	0.1% (2)	
	Other % (N)	2.6% (44)	0.7% (14)	
PPV23 Vaccination	No % (N)	57.4% (967)	57.6% (1171)	0.99
	Under 6 months % (N)	3.6% (60)	3.5% (72)	
	Over 6 months % (N)	39.1% (659)	38.8% (789)	
	Missing % (N)	0.0% (0)	0.0% (1)	
Non Invasive Ventilation	Yes % (N)	2.3% (39)	5.1% (103)	<0.001
Intubation	Yes % (N)	14.0% (236)	11.5% (234)	0.026
Inpatient Death	Yes % (N)	15.1% (255)	12.4% (253)	0.019

Significance determined using Fisher's exact test (categorical variables) or 2 sample Kolmogorov-Smirnov test, 2 sample Wilcoxon Rank Sum test (continuous variables) Normality of distributions determined using Anderson-Darling normality test

CCI, Charlson Comorbidity Index; CSF, cerebrospinal fluid; ENT, Ear, nose and throat; IQR, interquartile range; N, number; PCR, polymerase chain reaction; PPV23, pneumococcal polysaccharide vaccine 23-valent; UAT, urine antigen test

Figure One: Distribution of pneumococcal serotypes in hospitalised patients
(A) Incidence of total pneumococcal disease in Bristol, UK, 2006-2022. Data shown include invasive and non-invasive disease. Black dots represent monthly observations and the black line a binomial time series model with grey bars representing 95% confidence intervals. Population estimates are provided in Supplementary Data 3.
(B) Multinomial proportion of pneumococcal serotypes, in the invasive pneumococcal disease population with known serotype. Green bars represent PCV7 serotypes; orange, PCV13-7; purple, PCV15-13; pink, PCV20-15; grey, serotypes not contained in PCV vaccines. Individual serotypes are shown in the legend on the panel.
(C) The testing rates for blood cultures with respect to acute admissions and BinaxNOW tests with respect to acute respiratory admissions. Estimates are presented at the mid-year time point, relative to the data they represent.
For all panels, vertical lines indicate the introduction of PCV7 (solid black), PCV13 (2+1 schedule) (thin black dash), PCV13 (1+1 schedule) (thick black dash) into the UK childhood vaccination programme and the beginning of significant hospital admissions in Bristol due to SARS-CoV-2 (grey solid).

Figure Two: Distribution of pneumococcal serotypes in hospitalised patients following the emergence of SARS-CoV-2
The proportion of pneumococcal disease attributable to (A) each serotype and (B) by PCV vaccine group in Bristol, UK, from the 129 cases admitted between 1st Jan 2021 and 31st Dec 2022. Further data and time points are available in Supplementary Data 4. (C) Binomial (one versus others) time series models showing the proportion of disease from Jan 2006 - Dec 2022 which was attributable to each of the six most common serotypes (3, 8, 9N, 19F, 19A, 22F). Solid lines represent smoothed point estimates with 95% confidence intervals shown as pale coloured areas. The confidence intervals in panels A&B do not coincide exactly with those in C as they represent different length time periods and use different models. For all panels, green bars represent PCV7 serotypes; orange, PCV13-7; purple, PCV15-13; pink, PCV20-15; grey, serotypes not contained in PCV vaccines).

Figure Three: Severity of presentation and outcome of invasive pneumococcal disease over time
The proportion of invasive pneumococcal disease in hospitalised adults by (A) age category, (B) CURB65 score, (C) ICU admissions, (D) inpatient mortality and (E) hospital admission length. For panels (A), (B) and (E), categories are shown in the legend adjacent to each panel. The solid line in the multinomial time series models shown in panels (C) and (D) represent binomial time series models with 95% confidence intervals illustrated as grey area. Across all panels, the vertical lines denote the dates of PCV7 (solid black) and PCV13 2+1 (thin black dash) and 1+1 (thick dash black) schedule vaccine introduction and SARS-CoV-2 emergence (solid grey). Results for non-invasive pneumococcal disease are shown in Supplementary Data 5.

DISCUSSION

This study examining hospitalised adults with pneumococcal disease in Bristol and Bath encompasses 17 years of PCV implementation into the UK childhood vaccination programme, and includes three years of the COVID-19 pandemic. While the incidence of PCV serotype IPD has declined across all age groups, a significant proportion of adult pneumococcal disease is still caused by PCV7 (7.0% [3.7–12.7]) and PCV13-7 (21.7% [15.5–29.6]) serotypes [5,21]. Additionally, the proportion of adult disease due to these serotypes has increased since COVID-19 pandemic restrictions began in March 2020, which coincided with a change in the UK childhood immunisation schedule from three to two doses of PCV13 since April 2020. The persistence of PCV13 and PCV7-serotype disease in adults in this study occurs in the context of a long-standing, high coverage national childhood vaccination programme. This suggests that although giving PCVs to most children has had some indirect effects, these do not completely protect adults from PCV-serotype disease. The persistence of some PCV13 serotypes is concerning because they are associated with more severe disease and deaths in adults. Additionally, we have observed large increases in non-PCV13 serotype disease since PCV13 implementation, consistent with national surveillance throughout the UK and Europe [5-7,10, 21]. In 2016-2019 and 2021-2022, 78.8% [75.2–82.1] and 71.3% [63.0–78.4] of cases among those with identified serotypes were due to non-PCV13 serotypes, respectively. In 2021-22, PCV20-13 serotypes accounted for 39.5% [31.5–48.2] of adult disease with identified serotypes.

Despite indirect effects operating to some degree, PCV serotypes continue to cause adult disease which is severe enough to require hospital admission. Although PCV7 serotypes remain rare causes of adult pneumococcal disease, serotype 19F has re-emerged. We find that most residual PCV serotype disease is due to PCV13-7 serotypes, especially serotypes 3 and 19A;

observations which align with other reports [5,7,10,21]. The continued circulation of serotype 3, especially after the pandemic restrictions were lifted, is important, as this serotype is associated with more severe disease, especially in older adults. Ongoing circulation may, in part, be due to clade II expansion following clade distribution shift [24]. Serotype 19A is also of concern because it has previously been associated with high antibiotic resistance rates in some countries [25]. Indirect effects of PCVs are thought to occur via reduction in nasopharyngeal carriage and density of vaccine serotypes in vaccinated children, which interrupts transmission to both vaccinated and unvaccinated contacts [2–4]. Generally, sustained high PCV coverage in children is assumed to result in reliable indirect effects in adults: notably, the UK 1+1 PCV13 childhood immunisation schedule relies, to a degree, on these indirect effects, to protect infants who only receive one priming PCV dose before their one-year booster [22]. However, we cannot explain the recent increase in PCV13-serotype disease we observed by falling paediatric PCV vaccination rates. In the UK, vaccination is offered free of charge and associated with high uptake and PCV uptake was >90% and >94% for the first and second PCV dose by 12-months and 24-months in South-West England in 2021-22, respectively [23].

Concerning, too, is the high proportion of cases that are currently not vaccine preventable: during 2016-19, PCV20-13 and non-PCV serotypes represented 53.0% [48.8–57.2] and 25.8% [22.3–29.7], changing to 39.5% [31.5–48.2] and 31.8% [24.4–40.2] in 2021-2022, respectively. In 2021-22, PCV15 serotypes represented 34.9% [27.2–43.4] of IPD, PCV20 represented 68.2% [59.8–75.6] and non-PCV serotypes represented 31.8% [24.4–40.2] of total disease. Interestingly, although serotype replacement has been observed in both Europe and serotype distribution change in the US [5–7,21,26, 27]: reports from the US describe consistently stable rates of non-PCV13 serotype IPD after childhood PCV13 introduction [28]. Serotype replacement may occur through expansion of non-PCV strains or capsular switching of previously vaccine-preventable strains, in which recombination at the capsular gene locus

results in serotype change [29]. In concordance with others, we find serotype 8 disease increasing, along with 23A and 9N [5,7,10].

Early in the COVID-19 pandemic we observed a disproportionate decrease in pneumococcal disease incidence, without a concomitant decrease in BinaxNOW and blood culture testing rates. This may have been due to reduced circulation and transmission of many respiratory pathogens, including pneumococcus, due to social distancing policy implementation [11,12,14], breaking transmission chains and affecting host-pathogen-pathogen interactions, so that severe pneumococcal infection became less common. Preceding viral infection is a major risk factor for pneumonia, and the relationships between influenza and RSV and pneumococcus are well described [30,31]. Pneumococcus may also modulate host immune responses to SARS-CoV-2 [32]. Prospective surveillance demonstrates that Europe experienced significant and sustained reductions in invasive disease due to pneumococcus, *H. influenzae*, and *N. meningitidis* in early 2020 [33]. Our study confirms that reduced testing practices in hospitals do not explain such reductions. However, changes in healthcare utilisation, , may explain the incidence decreases that occurred. For example, vulnerable patients had fewer admissions to secondary care during the pandemic [34]. An increased admission threshold or avoidance of secondary care would increase community-level management of cases and reduce cases of pneumococcal disease presenting, and consequently being diagnosed, in hospitals. Since fewer investigations are performed in community-level care, such cases would be missed by surveillance that is reliant on microbiological testing.

By combining microbiological results with clinical data, we are able to report on both disease epidemiology and severity over time. We found some evidence of more severe disease

especially following SARS-CoV-2 emergence. The observed disruption to the broadly stable previous trends in disease severity during the early part of the SARS-CoV-2 pandemic may be a result of observation bias, a consequence of the pandemic, or both. While ICU admission rates increased for pneumococcal disease, we observed a reduction in admission CURB65 severity scores, consistent with the 2018 BTS national pneumonia audit which also reported decreased admission CURB65 scores [35]. This apparent discrepancy might be explained by changes in patients or their treatment: for example, older patients with more severe disease may be less likely to receive ICU care than younger patients due to clinical prognostic decision making. Other recent changes in treatment, such as increased availability of positive pressure support or earlier antibiotic administration, may also have changed patient courses and outcomes, including severity and mortality. Significant changes in pneumococcal infection severity have occurred since 2020, including an increased proportion of adults aged 45-55y who required hospital treatment. The recent increase in cases is probably related to relaxation of COVID-19 restrictions. Recent studies highlight the critical role of respiratory viruses (e.g. RSV, human metapneumovirus, influenza) in contributing to pneumococcal disease [15]. Large, out of season viral outbreaks which occurred following easing of COVID-19 restrictions [36] are therefore likely to have contributed to increasing pneumococcal disease reported here, which will need careful surveillance in future years. Independent of changes in clinical practice, serotype distribution changes may affect patient outcomes and healthcare usage as invasive potential varies by serotype.

This study has many strengths. We identified patients with pneumococcal infection in a population of approximately one million adults. We report disease over a 17-year period with epidemiological data supported by detailed clinical information at an individualised patient level. Data on admission numbers and testing practices allow us to interpret incidence considering

these factors, which might otherwise bias the estimate obtained. Linkage with the UKHSA national reference laboratory allows us to report serotype data whenever available, strengthening this study considerably. Importantly, our study also reports pneumococcal disease confirmed by UAT: this is not detected by national surveillance and allows us to estimate pneumococcal disease incidence and burden more accurately. The study also has some limitations. The UAT does not identify serotype: we were thus unable to report serotype data in 60% of our cohort; however, patients with known and unknown serotype disease had broadly similar demographic, clinical characteristics and outcomes. UAT has a sensitivity of 65% and test results may remain positive for some time after pneumococcal disease has been treated [37]. Although the data are concordant with national UKHSA epidemiological and BTS pneumonia audit data [35], providing significant reassurance, this regional study may not be representative of other regions or populations. As a retrospective observational study, only information as documented in medical records could be included. Patient treatment decisions may have varied over time and by treating physicians, and systemic changes in patient treatment, healthcare provision or admission threshold and microbiological testing practices may have occurred.

In conclusion, this study provides evidence that PCV13 serotypes continue to cause disease in adults, suggesting indirect effects of the childhood PCV programme may not lead to further reductions in the current residual burden of these serotypes in adults. Following the COVID-19 pandemic, serotype distribution changes have resulted in an increase in adult pneumococcal disease attributable to PCV serotypes, and a significant burden of current disease could be directly prevented by introducing PCV20 which has recently been licensed for adults. Ongoing surveillance of adult pneumococcal disease is vital to evaluate vaccine impact and monitor

replacement disease. The extent of indirect effects of PCVs should continue to be carefully

evaluated and considered in formulating future public health policy recommendations.

REFERENCES

Pneumococcal: the green book, chapter 25. GOV.UK. 2022. https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25 (accessed 10 Mar 2023).

Chan J, Nguyen CD, Dunne EM, *et al.* Using pneumococcal carriage studies to monitor vaccine impact in low- and middle-income countries. *Vaccine* 2019;**37**:6299–309. doi:10.1016/j.vaccine.2019.08.073

Loughlin AM, Hsu K, Silverio AL, *et al.* Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts' children. *Pediatr Infect Dis J* 2014;**33**:504–10. doi:10.1097/INF.0000000000000279

Simell B, Auranen K, Käyhty H, *et al.* The fundamental link between pneumococcal carriage and disease. *Expert Rev Vaccines* 2012;**11**:841–55. doi:10.1586/erv.12.53

Ladhani SN, Collins S, Djennad A, *et al.* Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. *Lancet Infect Dis* 2018;**18**:441–51. doi:10.1016/S1473-3099(18)30052-5

Miller E, Andrews NJ, Waight PA, *et al.* Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. *Lancet Infect Dis* 2011;**11**:760–8. doi:10.1016/S1473-3099(11)70090-1

Waight PA, Andrews NJ, Ladhani SN, *et al.* Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. *Lancet Infect Dis* 2015;**15**:535–43. doi:10.1016/S1473-3099(15)70044-7

Holubar M, Stavroulakis MC, Maldonado Y, *et al.* Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis. *PloS One* 2017;**12**:e0172414. doi:10.1371/journal.pone.0172414

Temple B, Toan NT, Uyen DY, *et al.* Evaluation of different infant vaccination schedules incorporating pneumococcal vaccination (The Vietnam Pneumococcal Project): protocol of a randomised controlled trial. *BMJ Open* 2018;**8**:e019795. doi:10.1136/bmjopen-2017-019795

Pick H, Daniel P, Rodrigo C, *et al.* Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013–18. *Thorax* 2020;**75**:38–49. doi:10.1136/thoraxjnl-2019-213725

Amin-Chowdhury Z, Aiano F, Mensah A, *et al.* Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Prospective National Cohort Study, England. *Clin Infect Dis Off Publ Infect Dis Soc Am* 2021;**72**:e65–75. doi:10.1093/cid/ciaa1728

Chow EJ, Uyeki TM, Chu HY. The effects of the COVID-19 pandemic on community respiratory virus activity. *Nat Rev Microbiol* 2023;**21**:195–210. doi:10.1038/s41579-022-00807-9

HM Government. Social Distancing Review. 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/999413/Social-Distancing-Review-Report.pdf (accessed 10 Mar 2023).

Choi YH, Miller E. Impact of COVID-19 social distancing measures on future incidence of invasive pneumococcal disease in England and Wales: a mathematical modelling study. *BMJ Open* 2021;**11**:e045380. doi:10.1136/bmjopen-2020-045380

Dagan R, Beek BA van der, Ben-Shimol S, *et al.* The COVID-19 pandemic as an opportunity for unravelling the causative association between respiratory viruses and pneumococcus-associated disease in young children: a prospective study. *eBioMedicine* 2023;**90**. doi:10.1016/j.ebiom.2023.104493

Lim WS, Baudouin SV, George RC, *et al.* BTS guidelines for the management of community acquired pneumonia in adults: update 2009. *Thorax* 2009;**64**:iii1–55. doi:10.1136/thx.2009.121434

Brown LD, Cai TT, DasGupta A. Interval Estimation for a Binomial Proportion. *Stat Sci* 2001;**16**:101–33. doi:10.1214/ss/1009213286

Ripley BD. *Pattern Recognition and Neural Networks.* Cambridge: : Cambridge University Press 1996. doi:10.1017/CBO9780511812651

Loader C. *Local Regression and Likelihood.* New York: : Springer-Verlag 1999. doi:10.1007/b98858

R Core Team. R: A language and environment for statistical computing. 2017.

Hanquet G, Krizova P, Dalby T, *et al.* Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe. *Emerg Infect Dis* 2022;**28**:137–8. doi:10.3201/eid2801.210734

Flasche S, Hoek AJV, Goldblatt D, *et al.* The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries. *PLOS Med* 2015;**12**:e1001839. doi:10.1371/journal.pmed.1001839

Childhood Vaccination Coverage Statistics- England, 2021-22. NDRS. https://digital.nhs.uk/data-and-information/publications/statistical/nhs-immunisation-statistics/2021-22 (accessed 10 Mar 2023).

Groves N, Sheppard CL, Litt D, *et al.* Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader. *Genes* 2019;**10**:845. doi:10.3390/genes10110845

Cassiolato A, Almeida S, Andrade A, *et al.* Expansion of the multidrug-resistant clonal complex 320 among invasive Streptococcus pneumoniae serotype 19A after the introduction of a ten-valent pneumococcal conjugate vaccine in Brazil. PLOS ONE 13(11): e0208211. https://doi.org/10.1371/journal.pone.0208211

Linden M van der, Falkenhorst G, Perniciaro S, *et al.* Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. *PLOS ONE* 2015;**10**:e0131494. doi:10.1371/journal.pone.0131494

Løchen A, Croucher NJ, Anderson RM. Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency. *Sci Rep* 2020;**10**:18977. doi:10.1038/s41598-020-75691-5

Ahmed SS, Pondo T, Xing W, *et al.* Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions—United States. *Clin Infect Dis* 2020;**70**:2484–92. doi:10.1093/cid/ciz739

Lewnard JA, Hanage WP. Making sense of differences in pneumococcal serotype replacement. *Lancet Infect Dis* 2019;**19**:e213–20. doi:10.1016/S1473-3099(18)30660-1

Sender V, Hentrich K, Henriques-Normark B. Virus-Induced Changes of the Respiratory Tract Environment Promote Secondary Infections With Streptococcus pneumoniae. *Front Cell Infect Microbiol* 2021;**11**.https://www.frontiersin.org/articles/10.3389/fcimb.2021.643326 (accessed 10 Mar 2023).

Weinberger DM, Klugman KP, Steiner CA, *et al.* Association between Respiratory Syncytial Virus Activity and Pneumococcal Disease in Infants: A Time Series Analysis of US Hospitalization Data. *PLOS Med* 2015;**12**:e1001776. doi:10.1371/journal.pmed.1001776

Mitsi E, Reiné J, Urban BC, *et al.* Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2. *J Clin Invest*;**132**:e157124. doi:10.1172/JCI157124

Brueggemann AB, Jansen van Rensburg MJ, Shaw D, *et al.* Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. *Lancet Digit Health* 2021;**3**:e360–70. doi:10.1016/S2589-7500(21)00077-7

Alqahtani JS, Oyelade T, Aldhahir AM, *et al.* Reduction in hospitalised COPD exacerbations during COVID-19: A systematic review and meta-analysis. *PLOS ONE* 2021;**16**:e0255659. doi:10.1371/journal.pone.0255659

National Adult Community Acquired Pneumonia Audit 2018/19 | British Thoracic Society | Better lung health for all. https://www.brit-thoracic.org.uk/quality-improvement/clinical-audit/national-adult-community-acquired-pneumonia-audit-201819/ (accessed 10 Mar 2023).

UKHSA. Surveillance of influenza and other seasonal respiratory viruses in winter 2021 to 2022. 30th September 2022. Available at: https://www.gov.uk/government/statistics/annual-flu-reports/surveillance-of-influenza-and-other-seasonal-respiratory-viruses-in-winter-2021-to-2022. Last accessed 27th March 2023.

Hyams C, Williams MO, Williams P. Urinary antigen testing for pneumococcal pneumonia: is there evidence to make its use uncommon in clinical practice? ERJ Open Research Jan 2020, 6 (1) 00223-2019; DOI: 10.1183/23120541.00223-2019

ACKNOWLEDGEMENTS

The authors would like to acknowledge the research teams at The Royal United, North Bristol and University Hospitals of Bristol and Weston NHS Trusts.

DATA SHARING

The data used in this study are sensitive and cannot be made publicly available without breaching patient confidentiality rules. Therefore, individual participant data and a data dictionary is not available to other researchers.

SUPPLEMENTARY DATA

Supplementary Data 1: Serotypes contained within each pneumococcal vaccination and vaccine group.

Vaccination	Serotypes
PPV-23, PneumoVax®	1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F.
PCV-7, Prevenar®	4, 6B, 9V, 14, 18C, 19F and 23F
PCV-13, Prevenar13®	1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, & 23F
PCV-15, VAXNEUVANCE®	1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F
PCV-20, Prevenar20®	1, 3, 4, 5, 6A, 6B, 7F, 8, 9V,10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F
PCV13-7 serotypes	1, 3, 5, 6A, 7F, 19A
PCV15-13 serotypes	22F, 33F
PCV20-15 serotypes	8, 10A, 11A, 12F, 15B
PCV20-13 serotypes	8, 10A, 11A, 12F, 15B, 22F, 33F
Non-PCV serotypes	Any serotype not contained in PCV20 (and therefore PCV15, PCV13 and PCV7)

PCV, Pneumococcal conjugate vaccine; PPV-23, Pneumococcal polysaccharide vaccine, 23 valent

Supplementary Data 2: Demographic comparison between invasive disease with known serotype and those without known serotype

Variable	Characteristic	Serotype identified	No serotype	P value
		Value (N=1501)	Value (N=185)	
Age	Median [IQR]	66.1 [51.1—78.9]	64.1 [46.2—79.2]	0.42
Gender	Male % (N)	50.0% (750)	52.4% (97)	0.53
	Female % (N)	50.0% (751)	47.6% (88)	
Smoker	Non-smoker % (N)	29.0% (435)	32.4% (60)	0.6
	Ex-smoker % (N)	40.4% (607)	39.5% (73)	
	Current smoker % (N)	30.6% (459)	28.1% (52)	
CCI	Median [IQR]	4 [1—6]	4 [1—7]	0.71
Infection Site	Lung % (N)	87.1% (1308)	60.0% (111)	<0.001
	Meningitis % (N)	7.1% (106)	35.7% (66)	
	Septic arthritis % (N)	2.0% (30)	3.2% (6)	
	ENT % (N)	1.0% (15)	0.0% (0)	
	Other % (N)	2.8% (42)	1.1% (2)	
PPV23 Vaccination	No % (N)	57.4% (861)	57.3% (106)	0.99
	Under 6 months % (N)	3.6% (54)	3.2% (6)	
	Over 6 months % (N)	39.0% (586)	39.5% (73)	
Non Invasive Ventilation	Yes % (N)	2.5% (37)	1.1% (2)	0.31
Intubation	Yes % (N)	12.3% (184)	28.1% (52)	<0.001
Inpatient Death	Yes % (N)	14.3% (214)	22.2% (41)	0.0064

Significance determined using Fisher's exact test (categorical variables) or 2 sample Kolmogorov-Smirnov test, 2 sample Wilcoxon Rank Sum test (continuous variables) Normality of distributions determined using Anderson-Darling normality test

CCI, Charlson Comorbidity Index; ENT, ear, nose and throat; IQR, interquartile range; N, number; PPV23, pneumococcal polysaccharide vaccine 23-valent;

Supplementary Data 3: Population estimates in the over 16 age groups

Supplementary Data 4: Case number and proportion of disease attributable to each pneumococcal serotype, by vaccine group, from Jan 2021 - Dec 2022

Vaccine type	Serotype	2006-2009		2010-2015		2016-2019		2020 (pandemic)		2021-2022	
		Cases	Proportion [95% CI]	Cases	Proportion [95% CI]	Cases	Proportion [95% CI]	Cases	Proportion [95% CI]	Cases	Proportion [95% CI]
PCV7	subtotal	73/248	29.4% [24.1—35.4]	38/536	7.1% [5.2—9.6]	8/534	1.5% [0.8—2.9]	1/54	1.9% [0.3—9.8]	9/129	7.0% [3.7—12.7]
	4	8/248	3.2% [1.6—6.2]	5/536	0.9% [0.4—2.2]	3/534	0.6% [0.2—1.6]	0/54	0.0% [0.0—6.6]	1/129	0.8% [0.1—4.3]
	6B	6/248	2.4% [1.1—5.2]	4/536	0.7% [0.3—1.9]	0/534	0.0% [0.0—0.7]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
	9V	8/248	3.2% [1.6—6.2]	2/536	0.4% [0.1—1.4]	0/534	0.0% [0.0—0.7]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
	14	25/248	10.1% [6.9—14.5]	6/536	1.1% [0.5—2.4]	2/534	0.4% [0.1—1.4]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
	18C	5/248	2.0% [0.9—4.6]	3/536	0.6% [0.2—1.6]	0/534	0.0% [0.0—0.7]	0/54	0.0% [0.0—6.6]	1/129	0.8% [0.1—4.3]
	19F	8/248	3.2% [1.6—6.2]	5/536	0.9% [0.4—2.2]	3/534	0.6% [0.2—1.6]	1/54	1.9% [0.3—9.8]	6/129	4.7% [2.1—9.8]
	23F	13/248	5.2% [3.1—8.8]	13/536	2.4% [1.4—4.1]	0/534	0.0% [0.0—0.7]	0/54	0.0% [0.0—6.6]	1/129	0.8% [0.1—4.3]
PCV13-7	subtotal	85/248	34.3% [28.6—40.4]	157/536	29.3% [25.6—33.3]	105/534	19.7% [16.5—23.2]	5/54	9.3% [4.0—19.9]	28/129	21.7% [15.5—29.6]
	1	22/248	8.9% [5.9—13.1]	30/536	5.6% [3.9—7.9]	3/534	0.6% [0.2—1.6]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
	3	12/248	4.8% [2.8—8.3]	43/536	8.0% [6.0—10.6]	63/534	11.8% [9.3—14.8]	4/54	7.4% [2.9—17.6]	21/129	16.3% [10.9—23.6]
	6A	9/248	3.6% [1.9—6.8]	1/536	0.2% [0.0—1.0]	0/534	0.0% [0.0—0.7]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
	7F	22/248	8.9% [5.9—13.1]	49/536	9.1% [7.0—11.9]	10/534	1.9% [1.0—3.4]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
	19A	20/248	8.1% [5.3—12.1]	34/536	6.3% [4.6—8.7]	29/534	5.4% [3.8—7.7]	1/54	1.9% [0.3—9.8]	7/129	5.4% [2.7—10.8]
PCV13	total	158/248	63.7% [57.6—69.4]	195/536	36.4% [32.4—40.5]	113/534	21.2% [17.9—24.8]	6/54	11.1% [5.2—22.2]	37/129	28.7% [21.6—37.0]
Non-PCV13 serotype	total	90/248	36.3% [30.6—42.4]	341/536	63.6% [59.5—67.6]	421/534	78.8% [75.2—82.1]	48/54	88.9% [77.8—94.8]	92/129	71.3% [63.0—78.4]
PCV15-13	subtotal	29/248	11.7% [8.3—16.3]	63/536	11.8% [9.3—14.8]	62/534	11.6% [9.2—14.6]	4/54	7.4% [2.9—17.6]	8/129	6.2% [3.2—11.8]
	22F	17/248	6.9% [4.3—10.7]	44/536	8.2% [6.2—10.8]	42/534	7.9% [5.9—10.5]	4/54	7.4% [2.9—17.6]	8/129	6.2% [3.2—11.8]
	33F	12/248	4.8% [2.8—8.3]	19/536	3.5% [2.3—5.5]	20/534	3.7% [2.4—5.7]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
PCV15	total	187/248	75.4% [69.7—80.3]	258/536	48.1% [43.9—52.4]	175/534	32.8% [28.9—36.9]	10/54	18.5% [10.4—30.8]	45/129	34.9% [27.2—43.4]
Non-PCV15 serotype	total	61/248	24.6% [19.7—30.3]	278/536	51.9% [47.6—56.1]	359/534	67.2% [63.1—71.1]	44/54	81.5% [69.2—89.6]	84/129	65.1% [56.6—72.8]
PCV20-15	subtotal	38/248	15.3% [11.4—20.3]	133/536	24.8% [21.3—28.6]	221/534	41.4% [37.3—45.6]	17/54	31.5% [20.7—44.7]	43/129	33.3% [25.8—41.8]
	8	18/248	7.3% [4.6—11.2]	62/536	11.6% [9.1—14.6]	113/534	21.2% [17.9—24.8]	9/54	16.7% [9.0—28.7]	33/129	25.6% [18.8—33.7]
	10A	0/248	0.0% [0.0—1.5]	11/536	2.1% [1.1—3.6]	19/534	3.6% [2.3—5.5]	2/54	3.7% [1.0—12.5]	2/129	1.6% [0.4—5.5]
	11A	6/248	2.4% [1.1—5.2]	7/536	1.3% [0.6—2.7]	23/534	4.3% [2.9—6.4]	2/54	3.7% [1.0—12.5]	4/129	3.1% [1.2—7.7]
	12F	10/248	4.0% [2.2—7.3]	48/536	9.0% [6.8—11.7]	57/534	10.7% [8.3—13.6]	3/54	5.6% [1.9—15.1]	3/129	2.3% [0.8—6.6]
	15B	4/248	1.6% [0.6—4.1]	5/536	0.9% [0.4—2.2]	9/534	1.7% [0.9—3.2]	1/54	1.9% [0.3—9.8]	1/129	0.8% [0.1—4.3]
PCV20-13	total	67/248	27.0% [21.9—32.9]	196/536	36.6% [32.6—40.7]	283/534	53.0% [48.8—57.2]	21/54	38.9% [27.0—52.2]	51/129	39.5% [31.5—48.2]
PCV20	total	225/248	90.7% [86.5—93.7]	391/536	72.9% [69.0—76.5]	396/534	74.2% [70.3—77.7]	27/54	50.0% [37.1—62.9]	88/129	68.2% [59.8—75.6]
Non-PCV serotype	total	23/248	9.3% [6.3—13.5]	145/536	27.1% [23.5—31.0]	138/534	25.8% [22.3—29.7]	27/54	50.0% [37.1—62.9]	41/129	31.8% [24.4—40.2]
	2	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	1/534	0.2% [0.0—1.1]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
	9N	5/248	2.0% [0.9—4.6]	20/536	3.7% [2.4—5.7]	27/534	5.1% [3.5—7.3]	3/54	5.6% [1.9—15.1]	10/129	7.8% [4.3—13.7]
	17F	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	6/534	1.1% [0.5—2.4]	0/54	0.0% [0.0—6.6]	2/129	1.6% [0.4—5.5]
	20	1/248	0.4% [0.1—2.2]	4/536	0.7% [0.3—1.9]	9/534	1.7% [0.9—3.2]	4/54	7.4% [2.9—17.6]	4/129	3.1% [1.2—7.7]
	6C	2/248	0.8% [0.2—2.9]	23/536	4.3% [2.9—6.4]	3/534	0.6% [0.2—1.6]	1/54	1.9% [0.3—9.8]	1/129	0.8% [0.1—4.3]
	7C	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	5/534	0.9% [0.4—2.2]	1/54	1.9% [0.3—9.8]	5/129	3.9% [1.7—8.8]

10B	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	2/534	0.4% [0.1—1.4]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
12B	0/248	0.0% [0.0—1.5]	3/536	0.6% [0.2—1.6]	0/534	0.0% [0.0—0.7]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
13	0/248	0.0% [0.0—1.5]	1/536	0.2% [0.0—1.0]	1/534	0.2% [0.0—1.1]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
15A	2/248	0.8% [0.2—2.9]	24/536	4.5% [3.0—6.6]	20/534	3.7% [2.4—5.7]	2/54	3.7% [1.0—12.5]	5/129	3.9% [1.7—8.8]
15C	3/248	1.2% [0.4—3.5]	2/536	0.4% [0.1—1.4]	1/534	0.2% [0.0—1.1]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
16F	2/248	0.8% [0.2—2.9]	8/536	1.5% [0.8—2.9]	11/534	2.1% [1.2—3.7]	4/54	7.4% [2.9—17.6]	1/129	0.8% [0.1—4.3]
18A	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	1/534	0.2% [0.0—1.1]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
21	0/248	0.0% [0.0—1.5]	1/536	0.2% [0.0—1.0]	1/534	0.2% [0.0—1.1]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
22A	1/248	0.4% [0.1—2.2]	0/536	0.0% [0.0—0.7]	1/534	0.2% [0.0—1.1]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
23A	1/248	0.4% [0.1—2.2]	14/536	2.6% [1.6—4.3]	8/534	1.5% [0.8—2.9]	2/54	3.7% [1.0—12.5]	6/129	4.7% [2.1—9.8]
23B	0/248	0.0% [0.0—1.5]	11/536	2.1% [1.1—3.6]	6/534	1.1% [0.5—2.4]	3/54	5.6% [1.9—15.1]	2/129	1.6% [0.4—5.5]
24	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	1/534	0.2% [0.0—1.1]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
24F	0/248	0.0% [0.0—1.5]	6/536	1.1% [0.5—2.4]	9/534	1.7% [0.9—3.2]	1/54	1.9% [0.3—9.8]	1/129	0.8% [0.1—4.3]
27	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	2/534	0.4% [0.1—1.4]	0/54	0.0% [0.0—6.6]	1/129	0.8% [0.1—4.3]
28A	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	0/534	0.0% [0.0—0.7]	1/54	1.9% [0.3—9.8]	0/129	0.0% [0.0—2.9]
31	3/248	1.2% [0.4—3.5]	1/536	0.2% [0.0—1.0]	2/534	0.4% [0.1—1.4]	1/54	1.9% [0.3—9.8]	0/129	0.0% [0.0—2.9]
32B	0/248	0.0% [0.0—1.5]	1/536	0.2% [0.0—1.0]	1/534	0.2% [0.0—1.1]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
33D	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	2/534	0.4% [0.1—1.4]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
34	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	2/534	0.4% [0.1—1.4]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
35B	1/248	0.4% [0.1—2.2]	8/536	1.5% [0.8—2.9]	11/534	2.1% [1.2—3.7]	1/54	1.9% [0.3—9.8]	2/129	1.6% [0.4—5.5]
35C	0/248	0.0% [0.0—1.5]	2/536	0.4% [0.1—1.4]	0/534	0.0% [0.0—0.7]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
35F	0/248	0.0% [0.0—1.5]	10/536	1.9% [1.0—3.4]	3/534	0.6% [0.2—1.6]	2/54	3.7% [1.0—12.5]	1/129	0.8% [0.1—4.3]
37	0/248	0.0% [0.0—1.5]	1/536	0.2% [0.0—1.0]	0/534	0.0% [0.0—0.7]	1/54	1.9% [0.3—9.8]	0/129	0.0% [0.0—2.9]
38	2/248	0.8% [0.2—2.9]	5/536	0.9% [0.4—2.2]	2/534	0.4% [0.1—1.4]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]

Supplementary Data 5: Severity of presentation and outcome of non invasive pneumococcal disease over time

The proportion of non-invasive pneumococcal disease in hospitalised adults by (A) age category, (B) CURB65 score, (C) ICU admissions, (D) inpatient mortality and (E) hospital admission length. For panels (A), (B) and (E), categories are provided in the legend adjacent to each panel. The solid line in the multinomial time series models shown in panels (C) and (D) represent binomial time series models with 95% confidence intervals illustrated as grey area. Across all panels, the dates of PCV7 and PCV13 (2+1 and 1+1 schedule) vaccine introduction and SARS-CoV-2 emergence are shown. As this figure relies on UAT data the early part of the time series should be interpreted with caution as routine use was not fully established until around 2010.